This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
View Post 4 min This content is machine translated AID systems for type 1 diabetes New real-world data shows: AI makes the difference In hybrid closed-loop systems, algorithms control the automated insulin delivery (AID). Compared to conventional insulin administration, this not only has a favorable effect on HbA1c values, but also on patient-oriented…
View Post 4 min This content is machine translated Dual GIP/GLP-1 RA in type 2 diabetes Tirzepatide proves multiple benefits In the Phase III SURPASS study program, the dual receptor agonist tirzepatide performed convincingly. The results of several post-hoc analyses are now also available. At the annual meeting of the…
